Poseida Therapeutics, Inc. (PSTX) Tops Q3 EPS by 63c

Poseida Therapeutics, Inc. (NASDAQ: PSTX) reported Q3 EPS of $0.21, $0.63 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $71.75 million versus the consensus estimate of $16.25 million.

For earnings history and earnings-related data on Poseida Therapeutics, Inc. (PSTX) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Lantern Pharma (LTRN) files for 2.24M share offering by selling stockholders
• Battery X Metals adds auto industry advisor to board